Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Q3 2026 Earnings Presentation
20 slides from Prestige Consumer Healthcare's earnings presentation, Feb 5, 2026
Slide 1: Third Quarter FY 26 Results
Third Quarter FY 26 Results February 5, 2026
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, adjusted diluted E
Slide 3: Agenda for Today's Discussion
Agenda for Today’s Discussion I. Performance Update II. Financial Overview III. FY 26 Outlook THIRD QUARTER FY 26 RESULTS 3
Slide 4: I. Performance Update
I. Performance Update THIRD QUARTER FY 26 RESULTS
Slide 5: Q3 FY 26 Performance Update
Q3 FY 26 Performance Update ◼ Quarterly Revenue of $283.4 million, better than forecast Q3 FY 26 Sales ◼ Clear Eyes® supply improved sequentially for the second quarter in a row Drivers ◼ Benefits of broad distribution helped offset volatile consumer environment ◼ Gross Margin of 55.5%, as expected
Slide 6: Continued Line of Sight Into Eye Care Recovery
Continued Line of Sight Into Eye Care Recovery Eye Care Strategic Actions Executed Strategic Priorities for Calendar 2026 ◼ Invest to accelerate Pillar5 production capacity, Added two additional 3rd party suppliers in Q1 and particularly on new high-speed line Q3, respectively, providing substantial
Slide 7: II. Financial Overview
II. Financial Overview THIRD QUARTER FY 26 RESULTS
Slide 8: Q3 FY 26 Performance Highlights
Q3 FY 26 Performance Highlights (2.4%) Revenue of $283.4 million, down 2.2% vs. prior year excluding foreign currency(1) $283.4 $290.3 (7.7%) Adjusted EBITDA(2) of $90.9 million vs. $98.5 $90.9 $98.5 (6.6%) million prior year $1.14 $1.22 (2) Adjusted Diluted EPS(2) of $1.14 down 6.6% vs. Revenue Adj
Slide 9: FY 26 Third Quarter and YTD Consolidated Financial Summary
FY 26 Third Quarter and YTD Consolidated Financial Summary 3 Months Ended 9 Months Ended YTD Comments ◼ Organic Revenue(1) down 3.9% vs. prior year Q3 FY 26 Q3 FY 25 % Chg YTD FY 26 YTD FY 25 % Chg Total Revenue $ 283.4 $ 290.3 (2.4%) $ 807.1 $ 841.2 (4.1%) – Sales declines due to eye care supply Gr
Slide 10: Industry Leading Free Cash Flow Trends
Industry Leading Free Cash Flow Trends Free Cash Flow(2) Comments Q3 FY 26 Q3 FY 25 YTD FY 26 YTD FY 25 ◼ Total YTD Free Cash Flow(2) of $208.8 million up 13% vs. prior year – Full-year free cash flow outlook(5) of $245 million $208.8 or more unchanged $184.9 – Strong business attributes continue to
Slide 11: Disciplined Capital Allocation at Work
Disciplined Capital Allocation at Work Shares Repurchased FCF Yield LTM Peer Avg. FCF Yield 1 Invest in Current Brands to Drive Organic Growth $155 2 Pursue M&A That is Attractive to Shareholders $75 Ample Capacity to Pursue Brands & Portfolios of Scale 3 $46 Strategic Share Repurchases Balanced Sha
Slide 12: III. FY 26 Outlook
III. FY 26 Outlook THIRD QUARTER FY 26 RESULTS
Slide 13: Updated FY 26 Outlook
Updated FY 26 Outlook ◼ Benefitting from well-diversified portfolio and brand-building playbook ◼ Revenues of approximately $1,100 Top Line Trends — Expected organic revenue down approximately 3.0% — Anticipate improvement in Clear Eyes® shipments sequentially in Q4 ◼ Adjusted Diluted EPS(4) of appr
Slide 14: Q&A
Q&A THIRD QUARTER FY 26 RESULTS
Slide 15: Appendix
Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measures in the attached Reconciliation Schedules and / or our earnings release dated February 5, 2026 in the “About Non-GAAP Financial Measures” section. (2) EBITDA & EBITDA Mar
Slide 16: Reconciliation Schedules
Reconciliation Schedules Organic Revenue Change Three Months Ended December 31, Nine Months Ended December 31, 2025 2024 2025 2024 (In Thousands) GAAP Total Revenues $ 283,444 $ 290,317 $ 807,088 $ 841,244 Revenue Change (2.4%) (4.1%) Adjustments: Impact of foreign currency exchange rates - (534) -
Slide 17: Reconciliation Schedules (continued)
Reconciliation Schedules (continued) General & Administrative Three Months Ended December 31, Nine Months Ended December 31, 2025 2024 2025 2024 (In thousands) GAAP General and Administrative Expense $ 29,674 $ 26,182 $ 86,167 $ 81,159 GAAP General and Administrative Expense as a Percentage of 10.5%
Slide 18: Reconciliation Schedules (continued)
Reconciliation Schedules (continued) Adjusted Diluted EPS Three Months Ended December 31, Nine Months Ended December 31, 2025 2024 2025 2024 Adjusted Adjusted Adjusted Adjusted Net Income EPS Net Income EPS Net Income EPS Net Income EPS (In Thousands, except per share data) GAAP Net Income and Dilut
Slide 19: Reconciliation Schedules (continued)
Reconciliation Schedules (continued) Free Cash Flow Three Months Ended December 31, Nine Months Ended December 31, 2025 2024 2025 2024 (In Thousands) GAAP Net Income $ 46,696 $ 61,032 $ 136,373 $ 164,477 Adjustments: Adjustments to reconcile net income to net cash provided by operating activities as
Slide 20: PCH CONFIDENTIAL AND PROPRIETARY INFORMATION
PCH CONFIDENTIAL AND PROPRIETARY INFORMATION
Prestige Consumer Healthcare — Q3 2026 Earnings Presentation on 6ix